Impact of the ablation technique on release of the neuronal injury marker S100B during pulmonary vein isolation
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology..
AIMS: S100B, a well-known damage-associated molecular pattern protein is released acutely by central and peripheral nerves and upon concomitant denervation in pulmonary vein isolation (PVI). We aimed to investigate whether the ablation technique used for PVI impacts S100B release in patients with paroxysmal atrial fibrillation (AF).
METHODS AND RESULTS: The study population consisted of 73 consecutive patients (age: 62.7 ± 10.9 years, 54.8% males) undergoing first-time PVI with either radiofrequency (RF; n = 30) or cryoballoon (CB; n = 43) for paroxysmal AF. S100B determined from venous plasma samples taken immediately before and after PVI increased from 33.5 ± 1.8 to 91.1 ± 5.3 pg/mL (P < 0.0001). S100B release in patients undergoing CB-PVI was 3.9 times higher compared to patients with RF-PVI (ΔS100B: 21.1 ± 2.7 vs. 83.1 ± 5.2 pg/mL, P < 0.0001). During a mean follow-up of 314 ± 186 days, AF recurrences were observed in 18/71 (25.4%) patients (RF-PVI: n = 9/28, CB-PVI: n = 9/43). Univariate Cox regression analysis indicated that an increase in S100B was associated with higher freedom from AF in follow-up (hazard ratio per 10 pg/mL release of S100B: 0.83; 95% confidence interval: 0.72-0.95; P = 0.007).
CONCLUSION: The ablation technique used for PVI has an impact on the release of S100B, a well-established biomarker for neural damage.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology - 22(2020), 10 vom: 01. Okt., Seite 1502-1508 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Scherschel, Katharina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.06.2021 Date Revised 23.06.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/europace/euaa159 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314038809 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314038809 | ||
| 003 | DE-627 | ||
| 005 | 20231225151853.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/europace/euaa159 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1046.xml |
| 035 | |a (DE-627)NLM314038809 | ||
| 035 | |a (NLM)32830253 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Scherschel, Katharina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of the ablation technique on release of the neuronal injury marker S100B during pulmonary vein isolation |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.06.2021 | ||
| 500 | |a Date Revised 23.06.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. | ||
| 520 | |a AIMS: S100B, a well-known damage-associated molecular pattern protein is released acutely by central and peripheral nerves and upon concomitant denervation in pulmonary vein isolation (PVI). We aimed to investigate whether the ablation technique used for PVI impacts S100B release in patients with paroxysmal atrial fibrillation (AF) | ||
| 520 | |a METHODS AND RESULTS: The study population consisted of 73 consecutive patients (age: 62.7 ± 10.9 years, 54.8% males) undergoing first-time PVI with either radiofrequency (RF; n = 30) or cryoballoon (CB; n = 43) for paroxysmal AF. S100B determined from venous plasma samples taken immediately before and after PVI increased from 33.5 ± 1.8 to 91.1 ± 5.3 pg/mL (P < 0.0001). S100B release in patients undergoing CB-PVI was 3.9 times higher compared to patients with RF-PVI (ΔS100B: 21.1 ± 2.7 vs. 83.1 ± 5.2 pg/mL, P < 0.0001). During a mean follow-up of 314 ± 186 days, AF recurrences were observed in 18/71 (25.4%) patients (RF-PVI: n = 9/28, CB-PVI: n = 9/43). Univariate Cox regression analysis indicated that an increase in S100B was associated with higher freedom from AF in follow-up (hazard ratio per 10 pg/mL release of S100B: 0.83; 95% confidence interval: 0.72-0.95; P = 0.007) | ||
| 520 | |a CONCLUSION: The ablation technique used for PVI has an impact on the release of S100B, a well-established biomarker for neural damage | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Atrial fibrillation | |
| 650 | 4 | |a Autonomic nervous system | |
| 650 | 4 | |a Catheter ablation | |
| 650 | 4 | |a Cryoballoon | |
| 650 | 4 | |a Intracardiac nervous system | |
| 650 | 4 | |a Neuromodulation | |
| 650 | 4 | |a Radiofrequency | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a S100 Calcium Binding Protein beta Subunit |2 NLM | |
| 650 | 7 | |a S100B protein, human |2 NLM | |
| 700 | 1 | |a Hedenus, Katja |e verfasserin |4 aut | |
| 700 | 1 | |a Jungen, Christiane |e verfasserin |4 aut | |
| 700 | 1 | |a Münkler, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Willems, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Anwar, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Klatt, Niklas |e verfasserin |4 aut | |
| 700 | 1 | |a Eickholt, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer, Christian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology |d 1999 |g 22(2020), 10 vom: 01. Okt., Seite 1502-1508 |w (DE-627)NLM111066492 |x 1532-2092 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2020 |g number:10 |g day:01 |g month:10 |g pages:1502-1508 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/europace/euaa159 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2020 |e 10 |b 01 |c 10 |h 1502-1508 | ||